Acquisition Announced

Eli Lilly and Company acquisition of Ventyx Biosciences

US$1.2bn equity value

Announced 7 Jan 2026 · NASDAQ: VTYX · US$14.00 cash per share · 62% premium

Advisers

Ventyx Biosciences

Target

Financial adviser
Fairness opinion

Eli Lilly and Company

Acquirer

Financial adviser
Legal adviser
Target
Ventyx Biosciences
Acquirer
Eli Lilly and Company
Target based in
United States
Buyer based in
United States
Sector
Biotech
Tags
Biotech, Drug Development, Pharma

In the league tables

Similar deals

All biotech deals →

Sources

Suggest a correction

A missing adviser, a wrong role or a different outcome. A link to a public source helps.